---
title: Effects of Peanut Intake on Cognitive Functions
nct_id: NCT05532007
overall_status: COMPLETED
phase: NA
sponsor: Loma Linda University
study_type: INTERVENTIONAL
primary_condition: Cognition
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05532007.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05532007"
ct_last_update_post_date: 2025-04-06
last_seen_at: "2026-05-12T06:32:50.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effects of Peanut Intake on Cognitive Functions

**Official Title:** Effects of Peanut Intake on Task-related Brain Activation and Cognitive Functions in Older Adults With Memory Complaints: A Randomized Controlled Study

**NCT ID:** [NCT05532007](https://clinicaltrials.gov/study/NCT05532007)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Loma Linda University
- **Collaborators:** The Peanut Institute
- **Conditions:** Cognition, Inflammation
- **Start Date:** 2022-03-29
- **Completion Date:** 2022-10-26
- **CT.gov Last Update:** 2025-04-06

## Brief Summary

The study will test the effects of Peanuts on task-related brain activation and cognitive functions in older adults with memory complaints.

## Detailed Description

The purpose of the study is to determine the effects of peanuts on cognitive performance and task-related brain activation on functional magnetic resonance imaging (fMRI) in older adults. The specific aim of the study is to explore the neuroprotective effects of a peanut-enriched diet (2-3 oz of peanuts to replace 20% of the total energy of the habitual diet) for 12 weeks compared to a peanut-excluded habitual diet in elderly men and women with increased risk for CVD and self-reported memory complaints. The study population is older adults 60-80 years in age.

## Eligibility

- **Minimum age:** 60 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Non-demented elderly between 60-80 years of age
* Self-reported memory complaints
* Two cardiovascular risk factors
* Stable weight for at least 6 months prior to recruitment

Exclusion Criteria:

* Peanut allergy
* Smoker
* Endocrine, metabolic and neuropsychological disorders
* Ineligible to get an MRI
* Consuming more than 3 servings/week of nuts including peanuts
```

## Arms

- **Peanut Group** (ACTIVE_COMPARATOR) — Peanuts: 2-3 ounces per day to replace 20% of daily energy intake
- **Control Group** (ACTIVE_COMPARATOR) — Habitual diet abstain from eating peanuts

## Interventions

- **Peanuts** (DIETARY_SUPPLEMENT) — 2-3 ounces of peanuts to replace 20% of total daily energy intake
- **Habitual Diet** (OTHER) — continue with habitual diet and abstain from eating peanuts

## Primary Outcomes

- **changes from baseline in Brian activation** _(time frame: baseline to 12 weeks)_ — Changes will be assessed by Functional MRI (fMRI) on participants. there is no units of measure
- **changes from baseline serum markers of inflammation** _(time frame: baseline to 12 weeks)_ — changes in serum inflammation markers which includes hs-CRP, IL-6, TNF-α, ICAM/VCAM, eSelectin, F2-isoprostanes, 8-hydroxy-deoxyguanosine (8-OH-dG) will all be assessed using ELISA

## Secondary Outcomes

- **changes from baseline in global cognitive composite score** _(time frame: baseline to 12 weeks)_
- **Change in serum brain-derived neurotrophic factor (pg/mL)** _(time frame: baseline to 12 weeks)_

## Locations (1)

- Loma Linda University School of Public Health, Loma Linda, California, United States

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.loma linda university school of public health|loma linda|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05532007.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05532007*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*